Phase 1 Study of Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2015
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Biotech Pharmaceutical
- 18 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as per ClinicalTrials.govrecord.
- 03 Oct 2009 New trial record